Get started
Author

Takahiro Ohashi

Observed name: T. Ohashi
ORCID: 0009-0001-4669-3119
Observed ORCID: 0009-0001-4669-3119
OpenAlex ID: A5138799279
Olanzapine increases hepatic glucose production through the activation of hypothalamic adenosine 5′‐monophosphate‐activated protein kinase
2013 · M. Ikegami, H. Ikeda, et al. · Diabetes Obesity and Metabolism · 65
Supplementary Figure S2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S3 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Table S2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S6 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S4 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Table S1 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S7 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S1 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S5 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Data from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Table 1 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Table S2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Figure 4 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Table 2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S3 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S7 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Figure 3 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Figure 5 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Table S1 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S4 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S1 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Figure 2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S5 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Works count: 30
Citation count: 65
H-index: 1
I10-index: 1
Year
Topic
Type